The study of ocular manifestations of neurodegenerative disorders, Oculomics, is a growing field of investigation for early diagnostics, enabling structural and chemical biomarkers to be monitored overtime to predict prognosis. Traumatic brain injury (TBI) triggers cascade of events harmful to the brain, which can lead to neurodegeneration. TBI, termed the silent epidemic is becoming a leading cause of death and disability worldwide. There is currently no effective diagnostic tool for TBI, and yet, early-intervention is known to considerably shorten hospital stays, improve outcomes, fasten neurological recovery and lower mortality rates, highlighting the unmet need for techniques capable of rapid and accurate point-of-care diagnostics, implemented in the earliest stages. This review focuses on the latest advances in the main neuropathophysiological responses and the achievements and shortfalls of TBI diagnostic methods. Validated and emerging TBI-indicative biomarkers are outlined and linked to ocular neuro-disorders. Methods detecting structural and chemical ocular responses to TBI are categorised along with prospective chemical and physical sensing techniques. Particular attention is drawn to the potential of Raman spectroscopy as a non-invasive sensing of neurological molecular signatures in the ocular projections of the brain, laying the platform for the first tangible path towards alternative point-of-care diagnostic technologies for TBI.
Traumatic brain injury (TBI), a major cause of morbidity and mortality worldwide, is hard to diagnose at the point of care with patients often exhibiting no clinical symptoms. There is an urgent need for rapid point-of-care diagnostics to enable timely intervention. We have developed a technology for rapid acquisition of molecular fingerprints of TBI biochemistry to safely measure proxies for cerebral injury through the eye, providing a path toward noninvasive point-of-care neurodiagnostics using simultaneous Raman spectroscopy and fundus imaging of the neuroretina. Detection of endogenous neuromarkers in porcine eyes’ posterior revealed enhancement of high–wave number bands, clearly distinguishing TBI and healthy cohorts, classified via artificial neural network algorithm for automated data interpretation. Clinically, translating into reduced specialist support, this markedly improves the speed of diagnosis. Designed as a hand-held cost-effective technology, it can allow clinicians to rapidly assess TBI at the point of care and identify long-term changes in brain biochemistry in acute or chronic neurodiseases.
The unique attributes of surface enhanced Raman spectroscopy (SERS) make it well suited to address the challenges associated with portable diagnostics. However, despite the remarkable progress in this field, where the instrumentation has made great strides forward providing a route to the miniaturization of sensing devices, to date producing three-dimensional low-cost SERS substrates which simultaneously fulfill the multitude of criteria of high sensitivity, reproducibility, tunability, multiplexity, and integratability for rapid sensing has not yet been accomplished. Successful implementation of SERS requires readily fine-tuned nanostructures, which create a high enhancement. Here, an advanced electrofluidynamic patterning (EFDP) technique enables rapid fabrication of SERS active topographic morphologies with high throughput and at a nanoresolution via the spatial and lateral modulation of the dielectric discontinuity due to the high electric field generated across the polymer nanofilm and air gap. The subsequent formation of displacement charges within the nanofilm by coupling to the electric field yield a destabilizing electrostatic pressure and amplification of EFDP instabilities enabling the controllable pattern formation. The top of each gold coated EFDP fabricated pillar generates controllable high SERS enhancement by coupling of surface plasmon modes on top of the pillar, with each nanostructure acting as an individual sensing unit. The absolute enhancement factor depends on the topology as well as the tunable dimensions of the nanostructured units, and these are optimized in the design and engineering of the dedicated EFDP apparatus for reproducible, low-cost fabrication of the three-dimensional nanoarchitectures on macrosurfaces, rendering them for easy integration in further lab-on-a-chip devices. This unique combination of nanomaterials and nanospectroscopic systems lay the platform for a variety of applications in chemical and biological sensing.
The global aging population presents a major public health challenge, with cardiovascular diseases (CVDs) remaining the leading cause of death worldwide. Often asymptomatic in early‐stages, CVDs are frequently undiagnosed until critical events like myocardial infarction or stroke occur. To address this gap, an advanced integrated multipurpose spectroscopic lab‐on‐a‐chip bionano‐device has been developed for early CVD detection through extracellular vesicle (EV). EVs, which reflect the molecular state of their originating cells, are separated and analyzed using the combined Raman spectroscopy's molecular specificity with AI‐driven classification from clinical CVD biofluids. AIMSpec‐LoC unprecedently achieves rapid, label‐free, size‐based separation of EV subtypes, including small, mid and large EVs from biofluids, whilst preserving EV integrity and eliminating extensive preprocessing. The device enables real‐time, multiplexed molecular profiling of EV cargo, identifying CVD‐specific biomarkers with sensitivity and specificity >96% and linking these to CVD progression, achieving >97% accuracy in identifying disease‐specific molecular fingerprints. This bionanotechnological device generates quantitative barcodes to support prognostic modeling and therapeutic evaluation, providing clinicians with actionable insights for timely‐diagnosis and personalized treatment. AIMSpec‐LoC platform offers a transformative solution for point‐of‐care CVD diagnostics, addressing critical unmet needs in cardiovascular medicine, enhancing clinical decision‐making, improving patient health and reducing the global burden of CVDs.